{
  "id": 667633,
  "title": "Dhoot Transmission, Molbio Diagnostics IPOs see over 70 times subscription on closing day",
  "url": "https://urgent.news/2026/08/12/dhoot-transmission-molbio-diagnostics-ipos-see-over-70-times",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-12T13:38:36.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/dhoot-transmission-molbio-diagnostics-ipos-see-over-70-times-subscription-on-closing-day/article71336323.ece"
  },
  "original_language": "en",
  "account": "Dhoot Transmission and Molbio Diagnostics experienced overwhelming demand during the final day of their IPO bids, with subscriptions reaching 74.21 times for Dhoot Transmission and 70.26 times for Molbio Diagnostics. The ₹3,067-crore Dhoot Transmission IPO saw the Qualified Institutional Buy (QIB) portion subscribed 212.92 times, while the Non-Institutional Investor (NII) category was booked 51.93 times. The retail and employee portions were subscribed 8.12 and 8.14 times, respectively. Anchors such as BlackRock, Abu Dhabi Investment Authority and SBI Mutual Funds contributed significantly to Dhoot Transmission's ₹918.3 crore raise. The company plans to use proceeds for debt repayment, subsidiary investments, and new manufacturing plants. Molbio Diagnostics raised ₹281.5 crore from anchor investors, including Temasek and Motilal Oswal Private Equity. The IPO's price band of ₹768-807 per share will see the company valued at around ₹9,300 crore post-issue. Both IPOs are expected to be listed on BSE and NSE on August 17.",
  "summary": "Dhoot Transmission QIB portion subscribed 212.92 times, NII 51.93 times; retail 8.12 times and employee portion 8.14 times",
  "key_points": [
    "Dhoot Transmission IPO saw 74.21 times subscription on closing day",
    "Molbio Diagnostics IPO saw 70.26 times subscription on closing day",
    "Both IPOs valued at around ₹9,300 crore post-issue"
  ],
  "editors_take": "The overwhelming subscription to Dhoot Transmission and Molbio Diagnostics IPOs indicates strong investor confidence, likely paving the way for successful listings on BSE and NSE.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}